Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy

Liu, Chao; Wu, Shikai; Meng, Xiao; Liu, Guangxian; Chen, Dongmei; Cong, Yang; Ge, Shuping; Sun, Bing; Wang, Wei; Wang, Qian; Gao, Hongjun; Liu, Xiaoqing

doi:10.18632/oncotarget.15238

Cited by 36 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, CD8+ T cells in cancer patients can lose the expression of CD28 due to the chronic stimulation of tumor antigens and consequently present with a non-responsive status to tumor antigens [28, 29]. We also reported this phenomenon in our previous study, as did other studies, that decreased CD8+CD28+ T cells and increased CD8+CD28− T cells were observable in NSCLC patients when compared with healthy volunteers [30–32]. In two recent studies, PD-1 inhibited the function of T cells by inactivating CD28 signaling, and PD-1-targeted therapies rescued CD28+ cells but not CD28− cells among CD8+ T cells, suggesting that CD28 signal plays vital roles in regulating the function of effector T cells [33, 34].…”

Section: Introductionsupporting

confidence: 66%

See 1 more Smart Citation

Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer

Liu

et al. 2019

J Transl Med

Self Cite

View full text Add to dashboard Cite

Background Stereotactic ablative radiotherapy (SABR) shows a remarkable local control of non-small cell lung cancer (NSCLC) metastases, partially as a result of host immune status. However, the predictors of immune cells for tumor response after SABR are unknown. To that effect, we investigated the ability of pre-SABR immune cells in peripheral blood to predict early tumor response to SABR in patients with lung metastases from NSCLC. Methods This study included 70 patients with lung metastases from NSCLC who were undergoing SABR. We evaluated the early tumor response 1 month and 6 months after SABR in these patients following RECIST 1.1 guidelines. Pre-SABR peripheral CD8+ T cell count, CD8+CD28+ T-cell count, CD8+CD28− T-cell count, CD4+ T-cell count, and Treg-cell count were measured using flow cytometry. Results Increased CD8+CD28+ T-cell counts (14.43 ± 0.65 vs. 10.21 ± 0.66; P = 0.001) and CD4/Treg ratio (16.96 ± 1.76 vs. 11.91 ± 0.74; P = 0.011) were noted in 1-month responsive patients, compared with non-responsive patients. In univariate logistic analyses, high CD8+CD28+ T-cell counts (OR 0.12, 95% CI 0.03–0.48; P = 0.003), CD4/Treg ratio (OR 0.24, 95% CI 0.06–0.90; P = 0.035), and BED 10 (OR 0.91, 95% CI 0.84–0.99; P = 0.032) predicted a 1-month tumor response to SABR. According to multivariate logistic analyses, the CD8+CD28+ T-cell count predicted a 1-month tumor response to SABR (OR 0.19, 95% CI 0.04–0.90; P = 0.037) independently. Furthermore, we confirmed the independent predictive value of the CD8+CD28+ T-cell count in predicting tumor response to SABR in 41 patients 6 months after treatment (OR 0.08, 95% CI 0.01–0.85; P = 0.039). Conclusions A pre-SABR CD8+CD28+ T-cell count could predict early tumor response to SABR in patients with lung metastases from NSCLC. Larger, independently prospective analyses are warranted to verify our findings. Electronic supplementary material The online version of this article (10.1186/s12967-019-1872-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionsupporting

confidence: 66%

“…The protocol for flow cytometry has been described in our previous study [30]. Four milliliters of fresh blood were collected and stored in EDTA anti-coagulate tubes within 7 days before SABR.…”

Section: Methodsmentioning

confidence: 99%

Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer

Liu

et al. 2019

J Transl Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several studies have demonstrated the association between the inflammatory system and tumors. The number of peripheral inflammatory cells before treatment, including lymphocytes, monocytes, and neutrophils, have shown the strong link between the prognosis of different kinds of cancer and the inflammatory system 22–32. Neutrophils, reportedly, is an indicator of inflammatory and immune response; their involvement in the proliferation and metastasis of tumor by releasing inflammatory factors, such as neutrophil elastase, matrix metalloproteinase-9, and interleukin-8 has been elucidated 33.…”

Section: Discussionmentioning

confidence: 99%

<p>Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer</p>

Wang

Yue

et al. 2019

CMAR

View full text Add to dashboard Cite

IntroductionThis research was conducted to explore the relationship between the systemic immune-inflammation index (SII) and breast imaging-reporting and data system (BI-RADS) classification using ultrasonography and the survival of patients with triple-negative breast cancer (TNBC) in a cohort of Chinese.MethodsA total of 215 TNBC patients treated at our hospital between November 2008 and March 2016 were enrolled in this study. We used the log-rank test and Kaplan–Meier curves to assess the overall survival (OS) and disease-free survival (DFS) differences between groups. The prognostic role of SII and other clinicopathological characteristics in TNBC patients were identified using the Cox regression model.ResultsPatients with low and high SII had median OS of 60.9 and 40.3 months, respectively, (HR=3.78, 95% CI: 2.16–4.15, P<0.001); while the median DFS was 22.4 months and 14.4 months for TNBC patients with low and high SII, respectively (HR =3.16, 95% CI: 1.82–4.02, P<0.001). For patients with grade 5 ultrasonographic BI-RADS classification, the median DFS and OS were 41.2 and 16.5 months, respectively, whereas, it was 57.7 and 21.3 months, respectively, for those with BI-RADS grades 3–4 (P<0.01). According to multivariable analyses, increased SII was a risk factor that independently predicted poor OS (HR =2.96, 95% CI: 2.18–3.98, P<0.001) and DFS (HR = 2.85, 95% CI: 1.62–3.81, P=0.005). In addition, tumor stage, BI-RADS, and histological grade also independently predicted poor OS (P=0.002, <0.001, 0.004).ConclusionPretreatment SII and BI-RADS 5 were independent indicators for prognosis in TNBC patients. It is imperative to conduct prospective studies to evaluate the potential role of SII in patient selection, treatment guidance, and design of clinical trials.

show abstract

“…22 A recent study displayed the increased proportions of Treg cells in NSCLC patients, and this may indicate tumor progression. 23 Another study observed that Treg cells, Th17 cells and Treg/Th17 ratio were increased in HCC patients. Treg/Th17 imbalance might serve as an important indicator for determining the progression and prognosis of HCC.…”

Section: Discussionmentioning

confidence: 99%

<p>Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients</p>

Qiu¹,

Zhou²,

Li³

et al. 2020

CMAR

View full text Add to dashboard Cite

The evaluation of lymphocyte subsets is widely regarded as an important factor for monitoring tumor progression and response to therapy. This study was designed to establish a comprehensive and detailed assessment of peripheral lymphocyte subsets with a multi-parametric flow cytometry assay for response prediction and prognosis evaluation of cancer patients. Methods: Peripheral blood samples collected from 40 cancer patients and 23 age-and sexmatched healthy volunteers were tested for 29 lymphocyte subsets by flow cytometry. The univariate analysis was applied to establish the reference interval of healthy samples, and the ratio and proportion of 29 lymphocyte subsets between patient samples and healthy controls were compared to evaluate their clinical significance by Mann-Whitney U-test model. Results: The reference ranges of 29 lymphocyte subsets were established with a normal distribution and no significant differences were observed between genders. Compared with healthy control group, lower proportion and ratio of specific parameters, such as Naïve Th cells (p<0.01), Naïve Tc cells (p<0.01), CM (central memory) Tc cells (p<0.01), Naïve T cells/ Memory T cells (p<0.001), Naïve T cells/EM (effector memory) T cells (p<0.001) and Naive Th cells/Memory Th cells (p< 0.001), and higher proportion and ratio of EM Th cells (p<0.001), EM Tc cells (p<0.01), effector Tc cells (p<0.05), EM Th cells/CM Th cells (p<0.01) and EM Tc cells/CM Tc cells (p<0.01), as well as Breg (p<0.001), B cells (p<0.05) and CD16-NK cells (p<0.001) were found in cancer cohorts. Conclusion: This study suggests that the changes in certain lymphocyte subsets might be helpful to evaluate the immunity of cancer patients, and holds great potential for clinical application.

show abstract

Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy

Cited by 36 publications

References 36 publications

Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer

Increased CD8+CD28+ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer

<p>Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer</p>

<p>Changes and Clinical Significance of Detailed Peripheral Lymphocyte Subsets in Evaluating the Immunity for Cancer Patients</p>

Contact Info

Product

Resources

About